Want to Join Our Team?
Learn about Blue Matter's innovative work experiences, enriching development opportunities, team-oriented "People First" culture, and a lot more.
Insights
Access our ever-expanding library of thought leadership resources for strategic leaders and professionals in biopharma. It’s full of useful content addressing industry challenges, best practices, therapeutic markets, innovative ideas, and forward-looking insights.
Featured Whitepaper
From Single Asset to Portfolio: Portfolio Strategy & Management for Expanding Biopharma Companies
Learn More >
Featured Whitepaper
Building Peak Performance Go-to-Market Operations: Capturing the Value of Medical Innovation in a Fast-Changing Landscape
Learn More >
Blog
7 “Make or Break” Factors for Emerging Biopharma Companies: Factor 7 – Establishing New Ways of Working
Whitepaper
The Convergence of Consumer Wearables & Medical Devices
Blog
The Convergence of Consumer Wearables & Medical Devices, Part 3: Opportunities for Consumer Wearables Manufacturers
Blog
7 “Make or Break” Factors for Emerging Biopharma Companies: Factor 6 – “Right-Sizing” the Launch
Blog
More Notes from ESMO 2023: Targeted Protein Degradation – The Promises of a New Generation?
Blog
More Notes from ESMO 2023: East Meets West
Blog
Notes from Madrid: Key Takeaways from the 2023 ESMO Congress
Blog
7 “Make or Break” Factors for Emerging Biopharma Companies: Factor 5 – Choosing the Best Commercial Path Forward
Whitepaper
Ensuring a Reliable Biopharmaceutical Supply in the EU
Blog
Ensuring a Reliable Biopharmaceutical Supply in the EU, Part 3: “Downstream” Strategies for Dealing with Complexity
Blog
The Convergence of Consumer Wearables & Medical Devices, Part 2: Opportunities for Medical Device Manufacturers
Blog
August 2023 Roundup of HTA Decisions in Three Top European Markets and a Perspective on How to Sustain a High ASMR Score at Reassessment by HAS
Blog
The Convergence of Consumer Wearables & Medical Devices, Part 1: Understanding the Convergence
Blog
Ensuring a Reliable Biopharmaceutical Supply in the EU, Part 2: “Upstream” Strategies for Dealing with Complexity
Blog
7 “Make or Break” Factors for Emerging Biopharma Companies: Factor 4 – Knowing What It Will Take to Commercialize
Blog
July 2023 Roundup of HTA Decisions in Oncology and a Perspective on the UK Cancer Drugs Fund (CDF)
